ID
22588
Beskrivning
Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche Study #: FVF4168g Drug: Ranibizumab Study Title: A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study Of The Efficacy And Safety Of Ranibizumab Injection In Subjects With Clinically Significant Macular Edema With Center Involvement Secondary To Diabetes Mellitus
Nyckelord
Versioner (1)
- 2017-06-08 2017-06-08 -
Rättsinnehavare
Genentech, Inc.
Uppladdad den
8 juni 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
INVESTIGATOR / SITE CHANGE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330
INVESTIGATOR / SITE CHANGE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330
Beskrivning
Study administration
Beskrivning
INV_NUMBER
Datatyp
integer
Alias
- UMLS CUI [1]
- C2826689
Beskrivning
SITE_NUMBER
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0018704
- UMLS CUI [1,2]
- C0600091
Beskrivning
Effective Date of Change: The date of subject’s first contact with the new investigator/site.
Datatyp
date
Måttenheter
- DD/MMM/YY
Alias
- UMLS CUI [1]
- C1302393
Similar models
INVESTIGATOR / SITE CHANGE (UNSCHEDULED) CRFs Roche FVF4168G Macular Edema NCT00473330
C2986440 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
Inga kommentarer